Catalyst Wire Dossier Catalyst Wire Dossier

abeLacimab

abeLacimab · Anthos Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for abeLacimab, covering 2025-07-30 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE [Phase 3]

See pricing